. 2016 Jun 17;7:171. doi: 10.3389/fphar.2016.00171

Table 1.

Overview on BAT applications for different drug classes, identification markers, acquisition conditions, observed activation patterns, and verification of IgE.

References	Drugs	Drug-specific serum IgE	Anti-coagulant	Basophil activation test protocols
				Basophil identification strategies	Stimulation conditions	Acquisition details
					Time [min] at 37°C	Activation marker	Basophils (n)	Cut-off
1. BETA-LACTAM ANTIBIOTICS
Eberlein et al., 2010	PCN G, PCN V, PPL, MDM, AMP, AX, CFX	Detected	EDTA	Strategy 1: SSC^low, IgE^pos	15	CD63	300	≥5%, SI ≥ 2
Abuaf et al., 2008	AX, AMP, CFX,	Not detected	HEP	Strategy 4⁺: SSC^low, CD33^dim, CD45^pos, IgE^pos	30	CD63, CD203c	200	Mean n.c.+ 2 × SD
De Week et al., 2009	PPL, MDM, BPN, AX, AMP, CEF	Detected	EDTA	Strategy 1: SSC^low, IgE^pos	40	CD63	500	≥5%, SI ≥ 2
Garcia-Ortega and Marin, 2010	AX	Detected	HEP	Strategy 1: SSC^low, IgE^pos	10^* + 20	CD63	1000	≥5%, SI ≥ 2
Sanz et al., 2002	BP, AMP, AX, MDM, PPL	Detected	ACD	Strategy 1: SSC^low, IgE^pos	40	CD63	500	≥5%, SI ≥ 2
Torres et al., 2010a	AX, DKP	Detected	HEP	Strategy 1: SSC^low, IgE^pos	10^* + 20	CD63	1000	SI(%)>2
Torres et al., 2004	AX, BP, BPP, AMP, MDM	Detected	HEP	Strategy 1: SSC^low, IgE^pos	10^* + 20	CD63	1000	SI(%)>2
Torres et al., 2011	AX	Detected	HEP	Strategy 1: SSC^low, IgE^pos	10^* + 20	CD63	1000	SI(%)>2
2. FLUOROQUINOLONES
Aranda et al., 2011	CPX, LVX, MOX	Detected	HEP	Strategy 1: SSC^low, IgE^pos	30	CD63	250–500	≥5%, SI ≥ 2
Mayorga et al., 2013	CPX, MOX	Not detected	HEP	Strategy 1: SSC^low, IgE^pos	30	CD63	250–500	≥5%, SI ≥ 2
Lobera et al., 2010	CPX, LVX, MOX, NFX	Not detected	HEP	Strategy 2: SSC^low, CD123^pos, HLA-DR^neg	15	CD63	200	≥5%, SI ≥ 2
Seitz et al., 2009	CPX, OFX, LVX, MOX	Not detected	EDTA	Strategy 1: SSC^low, IgE^pos	n.a.	CD63	n.a.	n.a.
Rouzaire et al., 2012	LVX, OFX, CPX, MOX, LMX, NFX, FLU, PPA	Not detected	HEP	Strategy 1⁺: SSC^low, IgE^pos, CD45^pos	10	CD203c	n.a.	>10%
Blanca-Lopez et al., 2013	NFX, CPX, LVX, MOX	n.a	HEP	Strategy 1: SSC^low, IgE^pos	30	CD63	250–500	≥5%, SI ≥ 2
Ben Said et al., 2010b	CPX, NFX, OFX	Not detected	n.a.	n.a.	n.a.	CD203c	n.a.	n.a.
3. NEURO-MUSCULAR BLOCKING AGENTS (NMBAs)
Ebo et al., 2007	ROC, SUX, MSO4, PHO	Detected	HEP	n.a.	n.a.	n.a.	n.a.	n.a.
Leysen et al., 2013	ROC, VEC, ATR, cATR, SUX	Detected	HEP	Strategy 1: SSC^low, IgE^pos	20	CD63, CD203c	n.a.	n.a.
Sainte-Laudy et al., 2006	ROC, VEC, cATR, SUX	Detected	EDTA	Strategy 1: SSC^low, IgE^pos	30	CD63	500	SI > 2
Ebo et al., 2006	ROC	Not detected	HEP	Strategy 2: SSC^low, CD123^pos, HLA-DR^neg	20	CD63	500	n.a.
Kvedariene et al., 2006	ROC, VEC, ATR, PANC, SUX	n.a	HEP	Strategy 1: SSC^low, IgE^pos	n.a.	CD63	1000	>15%
Monneret et al., 2002	ROC, VEC, ATR, MIV, SUX	Detected	n.a.	Strategy 3⁺⁺: SSC^low, CCR3^pos, IgE^pos, CD45^pos	10	CD63	n.a.	>2%
Monneret et al., 2000	ROC, SUX, PROP, MDL, ALF, THI	Detected	n.a.	n.a.	n.a.	CD63	n.a.	n.a.
Sudheer and Appadurai, 2007	VEC, cATR, SUC	Not detected	HEP	n.a.	n.a.	CD63	n.a.	n.a.
Sudheer et al., 2005	ROC, VEC, ATR, ALC, SUX	Not detected	HEP	Strategy 1⁺: SSC^low, IgE^pos, CD45^pos	15	CD63, CD203c	n.a.	>10%
Leysen et al., 2011	ROC, VEC	Detected	HEP	Strategy 2: SSC^low, CD123^pos, HLA-DR^neg	n.a.	CD63	n.a.	>4%
4. RADIO CONTRAST MEDIA (RCM)
Bohm et al., 2011	IOT, IOP	n.a	HEP	Strategy 1: SSC^low, IgE^pos	30	CD63	n.a	>5%
Pinnobphun et al., 2011	IOP, PM, IOB, IOH, IOX	n.a	EDTA	Strategy 3⁺: SSC^low, CCR3^pos, IgE^pos	n.a	CD63	500
Salas et al., 2013	IOH, IOD, IOM, IOB	Detected	n.a.	Strategy 1: SSC^low, IgE^pos	10^* + 20	CD63	1000	SI(%) > 2
Trcka et al., 2008	IOP, IOM, IPN	n.a	EDTA	Strategy 1: SSC^low, IgE^pos	n.a	CD63	500	>5%
5. PLATIN CHEMOTHERAPEUTICS
Iwamoto et al., 2014	CPT	detected	EDTA	n.a	30	CD203c	n.a	>2%
Iwamoto et al., 2012	CPT	n.a	EDTA	Strategy 5: SSC^low, CRTH-2^pos, CD3^neg	30	CD203c	n.a	>2%
6. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
Harrer et al., 2010	DF	Not detected	EDTA	Strategy 3: SSC^low, CCR3^pos	20	CD63	500–1000	≥%, SI ≥ 2
Steiner et al., 2011	PP	Detected	EDTA	Strategy 3: SSC^low, CCR3^pos	45	CD63	500	≥5%
Abuaf et al., 2012	ASA, ACET, KET, DF, CEL	n.a	HEP	Strategy 4: SSC^low, CD33^dim, CD45^pos	30	CD63, CD203c	400	Mean n.c. + 2 × SD
Bavbek et al., 2009	ASA, DF	n.a	ACD	Strategy 5: SSC^low, CRTH-2^pos, CD3^neg	40, 15	CD63, CD203c	n.a.	≥5%, SI > 2
Celik et al., 2009	ASA	n.a	EDTA	Strategy 6: SSC^low, FceRI^pos	180	CD63, CD203c	500	MFI, SI > 2
Gamboa et al., 2004b	ASA, ACET, MET, DF, NAP	n.a	ACD	Strategy 1: SSC^low, IgE^pos	40	CD63	500	≥5%, SI ≥ 2
Gamboa et al., 2003a	MET	n.a	ACD	Strategy 1: SSC^low, IgE^pos	40	CD63	500	≥5%, SI ≥ 2
Gomez et al., 2009	MET	n.a	HEP	Strategy 1: SSC^low, IgE^pos	30	CD63	250-500	≥5%, SI > 2
Hagau et al., 2013	DIP	n.a	EDTA	Strategy 3: SSC^low, CCR3^pos	15	CD63	500	≥5%, SI ≥ 1.71
Kim and Cho, 2012	ASA, IBU, DF	n.a	EDTA	Strategy 1: SSC^low, IgE^pos	40	CD63	n.a.	≥5%, SI ≥ 2
Korosec et al., 2011	ASA	n.a	HEP	Strategy 2: SSC^low, CD123^pos, HLA-DR^neg	15	CD63	500	% CD63 positive
Malbran et al., 2007	DF	n.a	HEP	Strategy 1⁺: SSC^low, IgE^pos, CD45^pos	15	CD63	200	Mean n.c. + 2 × SD
Sanz et al., 2005	ASA, ACET, MET, DF, NAP	n.a	ACD	Strategy 1: SSC^low, IgE^pos	40	CD63	500	≥5%, SI ≥ 2
Phillips-Angles et al., 2016	ETO, MET	Clinically excluded	HEP	Strategy 2: SSC^low, CD123^pos, HLA-DR^neg	15	CD63	500	≥5%, SI ≥ 2
7. OTHER DRUGS
Soriano Gomis et al., 2012	GA	Detected	n.a.	Strategy 1: SSC^low, IgE^pos	40	CD63	500	≥5%, SI ≥ 2
Aranda et al., 2010	MPS	Detected	HEP	Strategy 1: SSC^low, IgE^pos	n.a	CD63	1000	SI ≥ 2
Ben Said et al., 2010a	MPS	n.a.	n.a.	n.a.	n.a	CD203c	n.a	>2%
Gamboa et al., 2003b	OPZ	n.a	ACD	n.a.	n.a	CD63	n.a	SI
Apostolou et al., 2006	GF	n.a	HEP	Strategy 1: SSC^low, IgE^pos	20	CD63	n.a	>6%

1. Beta-lactam antibiotics: amoxicillin (AX), ampicillin (AMP), benzylpenicillin (BP), benzylpenicilloyl-PLL (BPN-PLL), cefuroxim (CFX), cephalosporins (CEPH), diketopiperazine (DKP), minor determinant mixture (MDM), penicillin G (PCN G), penicillin V (PCN V), penicilloyl polylysine (PPL); 2. Fluoroquinolones: ciprofloxacin (CPX), flumequin (FLU), levofloxacin (LVX), lomefloxacin (LMX), moxifloxacin (MOX), norfloxacin (NFX), ofloxacin (OFX), pipemidic acid (PPA); 3. NMBAs: alcuronium (ALC), alfentanyl (ALF), atracurium (ATR), cisatracurium (cATR), midazolam (MDL), mivacurium (MIV), morphine (MSO4), pancuronium (PANC), pholcodine (PHO), propofol (PROP), rocuronium (ROC), succinylcholine (SUC), suxamethonium (SUX), thiopental (THI), vecuronium (VEC); 4. RCM: iobitrididol (IBT), iodixanol (IDX), iohexol (IOH), iomeprol (IOM), iopamidol (IPM), iopentol (IPN), iopromide (IOP), iotrolan (IOT), ioxithalamate (IOX); 5. Chemotherapeutics: carboplatin (CPT), cisplatin (CsPT); 6. NSAIDs: acetaminophen (ACET), acetyl salicylic acid (ASA), celecoxib (CEL), diclofenac (DF), dipyrone (DIP), etoricoxib (ETO), ibuprofen (IBU), ketoprofen (KET), metamizol (MET), naproxen (NAP), propyphenazon (PP); 7. Other drugs: gelofusine (GF), glatiramer acetate (GA), methyolprednisolone (MPS), omeprazol (OPZ); ethylenediaminetetraacetic acid (EDTA), heparin (HEP), acid citrate dextrose (ACD); n.a., not available; SSC, side scatter; MFI, mean fluorescence intensity; n.c., negative control; n, number; SD, standard deviation; SI, stimulation index of MFI activated compared to n.c.; SI(%), stimulation index of %CD63-/CD203c-positive compared to n.c.; +/++ indicate use of one/two additional identification marker(s) on top of the respective gating strategy;

^*,

pre-stimulation in incubation buffer.